Zacks Investment Research on MSN3d
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...
GlobalData on MSN2d
Viking strikes $150m deal to secure supply of obesity drugViking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
In phase II and III trials of nearly 2,000 participants, the frequency of ARIA was 37% in the donanemab group compared with 14.2% in the placebo group, reported John Sims, MD, of Eli Lilly and ...
Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...
Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...
Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...
Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback